Professor Mark Garton

Professor Mark Garton

Consultant Physician and Rheumatologist

MD, FRCP(Edin), FRCP(London), MSc

I have broad experience in general medicine and rheumatology, and have a special interest in metabolic bone disease.

As a Consultant in Scotland and England, I have been involved in establishing and modernising bone density screening services, and have personally reported about 20,000 DXA scans since 2010. Over the last decade the greater part of my private and NHS practice has been focused on advising patients on how best to prevent and treat osteoporosis, taking account of personal preferences and the potential risks and benefits of drug interventions.

I studied at St George's Hospital Medical School in London, and qualified in 1985. Higher medical training followed in Scotland, including two years as a Wolfson Research Fellow attached to the Health Services Research Unit, University of Aberdeen. This provided ample research opportunities to complete my MD on strategies for the prevention of osteoporosis (1996), and a Masters in Public Health (1993).

Read more...

General Medical Council Number: 3063929

Treatment information

Some of the principal treatments carried out by Professor Mark Garton at Spire include:

Rheumatology

Get in touch

If you have an enquiry, or are an existing patient who needs to get in touch you can use our enquiry form to send us a message and we’ll get back to you.

Additional information

MB BS / University of London / 1985
Bachelor of Medicine Bachelor of Surgery
MB BS is a degree given to physicians on completion of basic training.

MSc Public Health / University of Aberdeen / 1993
Master of Science (Public Health)
MSc is an optional degree in a more specialised area.

MD / University of London / 1996
Doctor of Medicine
MD is a higher professional degree


Professional memberships

British Society for Rheumatology

Royal Osteoporosis Society

Bone Research Society

British Medical Association

I have participated in NHS research studies related to prevention of Paget's disease, and more recently into mitigation of the more severe effects of Covid 19 infection using a range of anti-inflammatory medications such as steroids and cytokine blockers. I have an interest also in studying similar interventions in patients with rheumatoid arthritis associated lung disease.


Articles

Garton M, McInnes IB, Sattar N. Comment on:Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis Rheumatology (Oxford). 2020 Feb 1;59(2):453-454. doi: 10.1093/rheumatology/kez613.

Garton M. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates (Letter). NEJM 2020; 383: 2189

Recovery collaborative group. Effect of hydroxychloroquine in hospitalised patients with Covid-19. NEJM 2020; 383: 2030-40

Medical Informatics Officer, Wrexham Maelor Hospital; Visiting Professor Wrexham Glyndwr University.

No financial interest in Spire Healthcare to declare. I hold a part-time post with Betsi Cadwaladr University Health Board, as a medical information officer for one day. a week, for a fixed term 3 year contract. I also have practising privileges at the Nuffield Hospital, Shrewsbury since 2017